RxDoctor Payments Data

Kathryn Arner, NP

Acute Care · Providence, RINPI 1720388655

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 43.1% of the total. Reporting peaked in 2024 at $945 and has fallen 70.8% since, to $276 in 2025.

$2,220in general payments, 2019–2025

Across 114 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$957
  • Phathom Pharmaceuticals, Inc.$416
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$154
  • Takeda Pharmaceuticals U.S.A., Inc.$122
  • Nestle Healthcare Nutrition Inc.$96
  • Gilead$89
  • plus $388 from 11 others

What the payments were for

  • Food & beverage$2,220100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,220 in reported general payments places this provider in the 85th percentile of 66 acute care providers in Rhode Island.

See all acute care providers in Rhode Island

Medicare billing

Part B allowed, 2024
$61,917
Medicare patients
477
Services billed
621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab24$241,558
LinzessLinaclotide95$58,078
IbsrelaTenapanor Hcl24$52,324
CreonLipase/Protease/Amylase22$36,911
Dexlansoprazole DrDexlansoprazole64$24,180
TrulancePlecanatide37$23,864
Mesalamine57$20,322
MotegrityPrucalopride Succinate18$17,848
DexilantDexlansoprazole26$16,887
Mesalamine ErMesalamine33$16,813
Omeprazole408$5,685
Esomeprazole Magnesium181$5,362
Budesonide EcBudesonide14$4,437
CholestyramineCholestyramine (With Sugar)26$4,158
Famotidine236$3,785

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$957$94,988117 claims
Ardelyx, Inc.Ibsrela$17$52,32424 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity, Dexilant$122$34,73544 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$154$23,86437 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 66 acute care providers in Rhode Island.

Other acute care in Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →